Live
Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospectFierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
FierceBiotech Dec 18, 2025

Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Original
Body unavailable. Use the original source.